SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 46.47 |
Enterprise Value ($M) | 37.32 |
Book Value ($M) | 9.03 |
Book Value / Share | 0.67 |
Price / Book | 5.15 |
NCAV ($M) | 8.50 |
NCAV / Share | 0.63 |
Price / NCAV | 5.46 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.50 |
Return on Assets (ROA) | -0.86 |
Return on Equity (ROE) | -1.12 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.15 |
Current Ratio | 4.15 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 15.69 |
Assets | 16.21 |
Liabilities | 7.18 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Soleus Private Equity Fund III, L.P. | 8.50 | ||
13G/A | Lytton Laurence W | 4.40 | -37.99 | |
13G/A | Stonepine Capital Management, LLC | 0.00 | -100.00 | |
13D/A | Valence Investments SPV VI, LLC | 9.00 | 4.67 | |
13G/A | Soleus Capital Master Fund, L.P. | 9.99 | 40.96 | |
13G/A | BML Investment Partners, L.P. | 2.10 | ||
13D/A | Orbimed Advisors Llc | 2.90 | 0.00 | |
13G | Aisling Capital V, LP | 5.10 | ||
13G | Flynn James E | 9.99 | 844.01 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
2,751 | 26,300 | 10.46 | |
5,616 | 17,563 | 31.98 | |
2,423 | 11,601 | 20.89 | |
4,002 | 25,332 | 15.80 | |
11,171 | 36,220 | 30.84 | |
(click for more detail) |
Similar Companies | |
---|---|
BPTH – Bio-Path Holdings, Inc. | BTAI – BioXcel Therapeutics, Inc. |
BYSI – BeyondSpring Inc. | CAPR – Capricor Therapeutics, Inc. |
CARA – Cara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io